Cabenuva® (cabotegravir and rilpivirine extended-release injectable suspension)

Covered as a complete HIV‑1 regimen for patients ≥12 years and ≥35 kg who are virologically suppressed (HIV‑1 RNA <50 copies/mL), have no history of treatment failure or known/suspected resistance to cabotegravir or rilpivirine, and who either were on a stable ARV regimen ≥4 months or completed the required oral lead‑in (per monthly or every‑2‑month initiation rules), with prescribing by or consultation with an HIV specialist and approvals limited to 12 months following the specified monthly or every‑2‑month dosing schedule. Excluded if age <12, weight <35 kg, HIV‑1 RNA ≥50 copies/mL, prior treatment failure or resistance, or failure to meet the initiation/or specialist prescriber and dosing documentation requirements.

"Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretrovira..."